Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 12/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553810 | 1.00 | C3AR1 (0.39) | C3AR1NPY1RBRD4BRD2BRD3 | |
| SCHEMBL4989542 | 0.88 | C3AR1 (0.44) | C3AR1NPY1R | |
| SCHEMBL4989549 | 0.88 | C3AR1 (0.44) | C3AR1NPY1R | |
| SCHEMBL14090798 | 0.82 | C3AR1 (0.35) | C3AR1BRD4BRD2BRD3BRDT | |
| SCHEMBL14115149 | 0.82 | C3AR1 (0.35) | C3AR1BRD4BRD2BRD3BRDT | |
| SCHEMBL14115720 | 0.82 | C3AR1 (0.35) | C3AR1BRD4BRD2BRD3BRDT | |
| SCHEMBL4994313 | 0.81 | C3AR1 (0.34) | C3AR1BRD4MMP8KDM4EALDH1A1 | |
| SCHEMBL4986631 | 0.80 | FOLH1 (0.38) | C3AR1NPY1RBRD4KDM4EALDH1A1 | |
| SCHEMBL4430961 | 0.80 | C3AR1 (0.37) | C3AR1NPY1RBRD4MMP8KDM4E | |
| SCHEMBL4429465 | 0.78 | C3AR1 (0.50) | C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | C3AR1 1/4885NPY1R 384/4885BRD4 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.